Search Results

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.

• Authors : Srivastava S; Department of Pulmonary Immunology, University of Texas Health Science Center, Tyler, Texas, USA.; Department of Immunology, UT Southwestern Medical Center, Dallas, Texas, USA.

Subjects: Lung Diseases*/Lung Diseases*/Lung Diseases*/microbiology ; Mycobacterium Infections, Nontuberculous*/Mycobacterium Infections, Nontuberculous*/Mycobacterium Infections, Nontuberculous*/drug therapy ; Mycobacterium Infections, Nontuberculous*/Mycobacterium Infections, Nontuberculous*/Mycobacterium Infections, Nontuberculous*/microbiology

• Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Apr 19; Vol. 66 (4), pp. e0232021. Date of Electronic Publication: 2022 Mar 22.Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium:

Record details

Agricola

Record details

Manipal Academy of Higher Education Researchers Add New Data to Research in Tuberculosis (Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients)

• Source: Obesity, Fitness & Wellness Week. June 27, 2020, 2484

Record details

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients.

• Authors : Thomas L; Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.; Sekhar Miraj S

• Source: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2020 Jun 08; Vol. 9 (6). Date of Electronic Publication: 2020 Jun 08.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382

Record details

Investigators at University of Texas at Tyler Discuss Findings in Mycobacterium kansasii (Rifampin Pharmacokinetics/pharmacodynamics In the Hollow-fiber Model of Mycobacterium Kansasii Infection)

• Source: Health & Medicine Week. May 20, 2022, 3092

Record details

Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico.

• Authors : Perea-Jacobo R; Laboratorio de Epidemiología y Ecología Molecular, Escuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Facultad de Ciencias Marinas, Universidad Autónoma de Baja California, Ensenada.; Muñiz-Salazar R

Subjects: Antitubercular Agents/Antitubercular Agents/Antitubercular Agents/*administration & dosage ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*complications ; Rifampin/Rifampin/Rifampin/*administration & dosage

• Source: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2019 Sep 01; Publisher: The Union Country of Publication: France NLM ID: 9706389 Publication Model: Print Cited Medium: Internet ISSN: 1815-7920 (Electronic)

Record details

Erratum for DeMarco et al., "Determination of [ 11 C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging".

• Authors : DeMarco VP; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

• Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Aug 23; Vol. 63 (9). Date of Electronic Publication: 2019 Aug 23 (Print Publication: 2019).Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium:

Record details

Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.

• Authors : Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee

Subjects: Infant, Premature/Infant, Premature/Infant, Premature/*metabolism ; Rifampin/Rifampin/Rifampin/*adverse effects ; Rifampin/Rifampin/Rifampin/*pharmacokinetics

• Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 May 24; Vol. 63 (6). Date of Electronic Publication: 2019 May 24 (Print Publication: 2019).Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium:

Record details

Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.

• Authors : Dompreh A; Department of Microbiology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.; Tang X

Subjects: Antitubercular Agents/Antitubercular Agents/Antitubercular Agents/*pharmacokinetics ; Arylamine N-Acetyltransferase/Arylamine N-Acetyltransferase/Arylamine N-Acetyltransferase/*genetics ; Carboxylesterase/Carboxylesterase/Carboxylesterase/*genetics

• Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Feb 23; Vol. 62 (3). Date of Electronic Publication: 2018 Feb 23 (Print Publication: 2018).Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium:

Record details

Investigators from Institute for Chemical Biology and Drug Discovery Zero in on Tuberculosis (Determination of [C-11] Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography ...).

• Source: Biotech Week. 2015, pages. 540

Record details